Search for: "LAMBERT v. STATE" Results 561 - 580 of 598
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
30 May 2008, 9:09 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: WHO members near accord on global strategy on IP and health: (Intellectual Property Watch), (GenericsWeb), (Gowlings), (IAM), Copiepresse seeks up to €49 million from Google in lawsuit over right to feature links to publishers’ content on internet: (IPKat), (Ars Technica), (Techdirt), (Out-Law), (IP Law360) Singapore ‘image… [read post]
20 Dec 2018, 6:27 am
In the wake of the UK Supreme Court decision in Warner-Lambert v Actavis (IPKat post here), second medical use claims have received considerable attention from the IP commentariat. [read post]
9 Nov 2015, 7:39 am
The patent therefore stated that inhibition of PD-1 or PD-L1 was effective in treating cancer.Claim breadth As well as deciding there was a clear and unambiguous disclosure, Birss J considered priority from the point of view of plausibility and claim breadth. [read post]
11 Jul 2008, 4:30 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: ACTA continues to be discussed and debated: (Michael Geist), (Intellectual Property Watch), (Public Knowledge),  (Techdirt), (Managing Intellectual Property), (Public Knowledge), (Public Knowledge), (Public Knowledge), Apotex challenge to Acular LS patent barred by res judicata: Roche Palo Alto & Allergan v Apotex:… [read post]
24 Apr 2012, 5:55 pm
That one way is spelled out, in very clear words, in Article V of ECUSA's Constitution, and it has not changed in over 200 years. [read post]
Although the Court of Appeal was clear, in Neurim v Generics [2020] EWCA Civ 793, that deciding to uphold the lower court’s decision not to grant a pharmaceutical patent PI was based on the specific facts of that case, the Patents Court has subsequently refused two further pharmaceutical PIs (Neurim v Teva [2022] EWHC 954 (Pat) and [2022] EWHC 1641(Pat), and Novartis v Teva [2022] EWHC 959 (Ch)). [read post]
24 May 2023, 3:55 pm by Keith Szeliga and Katie Calogero
Welcome back to the Cost Corner, where we provide practical insight into the complex cost and pricing regulations that apply to Government contractors. [read post]